Video

PCI Capacity Update July 2025: Small Molecule Drug Product/Finished Dosage Form

Join Dr. Rebecca Coutts as she highlights PCI’s high potent oral solid dose (OSD) and oral liquid capabilities, focusing on site expertise, specialized infrastructure, and handling of complex molecules. The session will also touch on solubility enhancement strategies for challenging compounds like targeted protein degraders (TPDs), and conclude with a clear view of current capacity available to support your high potent OSD programs.

access the Video!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Outsourced Pharma

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)

PCI Pharma Services